Skip to main content
Premium Trial:

Request an Annual Quote

U of Aberdeen Researcher Lands $200K to Study Protein Biomarkers for Colon Cancer

NEW YORK (GenomeWeb News) – A scientist at Scotland’s University of Aberdeen will use a £105,000 ($211,000) grant from the Association for International Cancer Research, a Scotland-based non-profit, to study proteins that could be used as diagnostics and therapeutics for early-stage colon cancer, the AICR said Wednesday. 
 
Graeme Murray at Aberdeen’s Department of Pathology said his team will use a “large collection” of colon cancer samples that include information about the stage of cancer, “and we will look for characteristic changes in the proteins of each to find out if we can use this information and knowledge to see if it can be used as a new way to diagnose the stages of this killer cancer.”
 
Although the outlook for patients with this type of cancer has improved significantly over the last 20 years, currently only about half of colon cancer patients survive five years after diagnosis, said AICR Scientific Officer, Mark Matfield.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.